Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort

Laura Q.M. Chow*, Robert Haddad, Shilpa Gupta, Amit Mahipal, Ranee Mehra, Makoto Tahara, Raanan Berger, Joseph Paul Eder, Barbara Burtness, Se Hoon Lee, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Jared Weiss, Ravit Geva, Chia Chi Lin, Hyun Cheol Chung, Amy Meister, Marisa Dolled-Filhart, Kumudu PathirajaJonathan D. Cheng, Tanguy Y. Seiwert

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort'. Together they form a unique fingerprint.

Medicine & Life Sciences